Literature DB >> 27613156

Mesenchymal stem cell-conditioned media ameliorate diabetic endothelial dysfunction by improving mitochondrial bioenergetics via the Sirt1/AMPK/PGC-1α pathway.

Yujia Yuan1, Meimei Shi1, Lan Li1, Jingping Liu1, Bo Chen1, Younan Chen1,2, Xingxing An1, Shuyun Liu1, Ruixi Luo1, Dan Long1, Wengeng Zhang1, Philip Newsholme2, Jingqiu Cheng1, Yanrong Lu3.   

Abstract

Vasculopathy is a major complication of diabetes. Impaired mitochondrial bioenergetics and biogenesis due to oxidative stress are a critical causal factor for diabetic endothelial dysfunction. Sirt1, an NAD+-dependent enzyme, is known to play an important protective role through deacetylation of many substrates involved in oxidative phosphorylation and reactive oxygen species generation. Mesenchymal stem cell-conditioned medium (MSC-CM) has emerged as a promising cell-free therapy due to the trophic actions of mesenchymal stem cell (MSC)-secreted molecules. In the present study, we investigated the therapeutic potential of MSC-CMs in diabetic endothelial dysfunction, focusing on the Sirt1 signalling pathway and the relevance to mitochondrial function. We found that high glucose-stimulated MSC-CM attenuated several glucotoxicity-induced processes, oxidative stress and apoptosis of endothelial cells of the human umbilical vein. MSC-CM perfusion in diabetic rats ameliorated compromised aortic vasodilatation and alleviated oxidative stress in aortas. We further demonstrated that these effects were dependent on improved mitochondrial function and up-regulation of Sirt1 expression. MSC-CMs activated the phosphorylation of phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt), leading to direct interaction between Akt and Sirt1, and subsequently enhanced Sirt1 expression. In addition, both MSC-CM and Sirt1 activation could increase the expression of peroxisome proliferator-activated receptor γ co-activator-1α (PGC-1α), as well as increase the mRNA expression of its downstream, mitochondrial, biogenesis-related genes. This indirect regulation was mediated by activation of AMP-activated protein kinase (AMPK). Overall our findings indicated that MSC-CM had protective effects on endothelial cells, with respect to glucotoxicity, by ameliorating mitochondrial dysfunction via the PI3K/Akt/Sirt1 pathway, and Sirt1 potentiated mitochondrial biogenesis, through the Sirt1/AMPK/PGC-1α pathway.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  endothelial dysfunction; mesenchymal stem cell-conditioned media; mitochondrial biogenesis; sirtuins

Mesh:

Substances:

Year:  2016        PMID: 27613156     DOI: 10.1042/CS20160235

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  24 in total

Review 1.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

2.  Salvianolic acid A promotes mitochondrial biogenesis and function via regulating the AMPK/PGC-1α signaling pathway in HUVECs.

Authors:  Xuelian Wang; Mi Zhang; Mengyao Zhang; Yantao Han; Xuehong Chen; Wenwen Zhao; Zhiwu Han; Jialin Sun
Journal:  Exp Ther Med       Date:  2022-06-01       Impact factor: 2.751

3.  Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling.

Authors:  Yi Liu; Jingan Chen; Haowei Liang; Yueqin Cai; Xinyue Li; Li Yan; Li Zhou; Letian Shan; Hui Wang
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

Review 4.  Histone Methylation and Oxidative Stress in Cardiovascular Diseases.

Authors:  Xin Yi; Qiu-Xia Zhu; Xing-Liang Wu; Tuan-Tuan Tan; Xue-Jun Jiang
Journal:  Oxid Med Cell Longev       Date:  2022-03-16       Impact factor: 6.543

5.  Biofunctionalized Scaffold in Bone Tissue Repair.

Authors:  Francesca Diomede; Marco D'Aurora; Agnese Gugliandolo; Ilaria Merciaro; Tiziana Orsini; Valentina Gatta; Adriano Piattelli; Oriana Trubiani; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2018-03-29       Impact factor: 5.923

6.  Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats.

Authors:  Alaaeldin Ahmed Hamza; Ebtehal Mohammad Fikry; Wedad Abdallah; Amr Amin
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

Review 7.  The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Pratik Chakraborty; Moumita Gangopadhyay; Ranabir Sahu; Vijaykrishna Medala; Albin John; P Hemachandra Reddy; Vincenzo De Feo; Ramesh Kandimalla
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

8.  Mesenchymal stem cell-derived conditioned medium protects vascular grafts of brain-dead rats against in vitro ischemia/reperfusion injury.

Authors:  Sevil Korkmaz-Icöz; Pengyu Zhou; Yuxing Guo; Sivakkanan Loganathan; Paige Brlecic; Tamás Radovits; Alex Ali Sayour; Mihály Ruppert; Gábor Veres; Matthias Karck; Gábor Szabó
Journal:  Stem Cell Res Ther       Date:  2021-02-24       Impact factor: 6.832

9.  MSC-derived cytokines repair radiation-induced intra-villi microvascular injury.

Authors:  Peng-Yu Chang; Bo-Yin Zhang; Shuang Cui; Chao Qu; Li-Hong Shao; Tian-Kai Xu; Ya-Qin Qu; Li-Hua Dong; Jin Wang
Journal:  Oncotarget       Date:  2017-09-23

10.  Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs-mediated CD8+ T cell responses.

Authors:  Fuping Zhang; Chengshi Wang; Xin Wen; Yang Chen; Ruiwen Mao; Danli Cui; Lan Li; Jingping Liu; Younan Chen; Jingqiu Cheng; Yanrong Lu
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.